“I am very impressed with the thoroughness of the analysis. I hope to steer more data your way soon. Again, thank you for undertaking this at a small cost. It is much appreciated.”
“Thanks for getting this back so quickly, and for the thoroughness of the design and report. We look forward to working with you again!”
“A pleasure to work with. Concise and detailed report for our 3D cell assay. We’ll have more projects your way soon!”
“Extremely impressive work, thanks for getting this back to us so quickly. I really appreciate the detailed analysis.”
Spotlight
NASH 3D Cell Culture Assays
Our expertise in 3D cell culture models and quantitative evaluation allows for an unparalleled evaluation of compounds which ameliorate the NASH continuum.
Biomarker Co-localization and Quantification
We perform quantitative analysis of distribution, colocalization and spatial relationships of biomarkers and cells detected in H&E, IF, multiplex IHC and ISH slides.
Tissue Analysis for Immuno-oncology
Automated analysis of the number, distribution, and infiltration of immune cell sub-types within tumor tissue specimens.
Featured Posts
Stop Calling Everything an Organoid! – 3D Cell Culture Terminology
As a company focused on 3D cell culture models and assays, we routinely have researchers ask us about organoid models and typically we always ask the researcher what exactly they mean by organoid. The [...]
Liver Steatosis: 2D and 3D Screening Platforms
Steatosis is characterized by abnormal retention of lipids within an organ and is most common within the liver due to the liver’s role in lipid metabolism. Excess lipid accumulation within the liver can be brought on by a variety [...]
Visikol Launches DILI 3D Cell Culture Assay Services Using Corning® Qualified 3D PHH Spheroid Assay-Ready Plates
Over the last few years, researchers have begun to transition from using traditional two-dimensional cell culture models for assessing drug induced liver injury (DILI) to more complex and relevant 3D cell culture models that [...]
Visikol Joins CELLINK
May 20th, 2021 - Today Visikol joins the CELLINK family through acquisition. The acquisition provides CELLINK the opportunity to enter into the $11.58 billion dollar contract research market, while Visikol is provided with access [...]
Digital Pathology Today Podcast
In this episode of Digital Pathology Today, Visikol CEO Michael Johnson, PhD discusses 3D imaging in digital pathology. We look at the current and future uses of 3D imaging. We talk about the current [...]
Examining gene expression with RT-qPCR
At Visikol, our services have grown from our expertise in cell culture, high-content tissue imaging, and advanced digital pathology. For nearly a year, however, our in vitro services have been augmented by gene expression [...]
